We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-6.02%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
-$325M
(-18%)
Cap. Flow
-$296M
Cap. Flow
% of AUM
-19.34%
Top 10 Holdings %
Top 10 Hldgs %
65.86%
Holding
300
New
43
Increased
68
Reduced
83
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$95.6M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
+$7.45M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$5.41M |
| 4 |
Microbot Medical
MBOT
|
+$4.73M |
| 5 |
United Therapeutics
UTHR
|
+$4.46M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$6.09M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$5.39M |
| 3 |
MTFB
Motif Bio plc ADRs
MTFB
|
+$4.6M |
| 4 |
OTIC
Otonomy, Inc.
OTIC
|
+$3.19M |
| 5 |
Palisade Bio
PALI
|
+$2.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 13% |
| 2 | Materials | 0.27% |
| 3 | Financials | 0.11% |
| 4 | Consumer Staples | 0.03% |
| 5 | Consumer Discretionary | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Merck
MRK
$326B
| $262M | 17.13% |
42,820
-1,639
| -4% | -$99.8K |
|
|
2
PUT
Bristol-Myers Squibb
BMY
$130B
| $186M | 12.14% |
33,296
+14,823
| +80% | +$807K |
|
|
3
Bristol-Myers Squibb
BMY
$130B
| $111M | 7.28% |
1,995,980
+1,756,800
| +735% | +$95.6M |
|
4
CALL
AstraZeneca
AZN
$267B
| $83.3M | 5.45% |
12,211
+4,874
| +66% | +$318K |
|
5
CALL
AbbVie
ABBV
$465B
| $81.8M | 5.35% |
11,276
-5,393
| -32% | -$363K |
|
6
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $79.8M | 5.22% |
3,301
-2,799
| -46% | -$671K |
|
7
CALL
Vertex Pharmaceuticals
VRTX
$124B
| $58.7M | 3.84% |
4,553
+3,177
| +231% | +$382K |
|
8
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $57.2M | 3.74% |
4,058
+958
| +31% | +$102K |
|
|
9
PUT
Merck
MRK
$326B
| $45.1M | 2.95% |
7,368
+3,881
| +111% | +$236K |
|
10
CALL
Cigna
CI
$79.6B
| $42.3M | 2.77% |
2,528
+948
| +60% | +$152K |
|
|
11
CALL
Bristol-Myers Squibb
BMY
$130B
| $27M | 1.77% |
4,851
-9,168
| -65% | -$499K |
|
|
CLVS
12
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $26.6M | 1.74% |
2,839
-413
| -13% | -$25.3K |
|
|
BLUE
13
CALL
DELISTED
bluebird bio
BLUE
| $26.2M | 1.71% |
192
+45
| +31% | +$54.3K |
|
14
PUT
Alnylam Pharmaceuticals
ALNY
$38.5B
| $19.1M | 1.25% |
2,391
-86
| -3% | -$5.5K |
|
15
CALL
Sarepta Therapeutics
SRPT
$1.63B
| $19M | 1.25% |
5,646
+1,597
| +39% | +$52K |
|
|
16
CALL
United Therapeutics
UTHR
$26.1B
| $17.7M | 1.16% |
1,363
-47
| -3% | -$5.86K |
|
|
17
CALL
Alnylam Pharmaceuticals
ALNY
$38.5B
| $13.7M | 0.89% |
1,714
-251
| -13% | -$16K |
|
|
18
PUT
United Therapeutics
UTHR
$26.1B
| $13.2M | 0.86% |
1,016
+117
| +13% | +$14.6K |
|
|
19
PUT
AstraZeneca
AZN
$267B
| $13M | 0.85% |
1,913
-206
| -10% | -$13.5K |
|
|
TSRO
20
PUT
DELISTED
TESARO, Inc.
TSRO
| $12.8M | 0.84% |
918
+221
| +32% | +$32K |
|
|
DVAX
21
CALL
DELISTED
Dynavax Technologies
DVAX
| $12.1M | 0.79% |
12,493
+733
| +6% | +$4.76K |
|
|
SIOX
22
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $11.2M | 0.73% |
602
+25
| +4% | +$4.38K |
|
|
23
PUT
Vertex Pharmaceuticals
VRTX
$124B
| $10.5M | 0.68% |
811
+269
| +50% | +$32.4K |
|
|
ALXN
24
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
| $9.73M | 0.64% |
800
-2,017
| -72% | -$235K |
|
|
CERN
25
CALL
DELISTED
Cerner Corp
CERN
| $9.31M | 0.61% |
+1,400
| New | +$89.5K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q2 2017 Portfolio in Review
As of Q2 2017, Sabby Management held 300 positions worth $1.53B, down 18% from $1.85B the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Sabby Management withdrew a net $296M in Q2 2017, closing 84 positions and reducing 83 holdings. Its most notable exit was Amgen, an estimated $6.09M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 6.3% a quarter earlier, followed by Materials and Financials.
Against the trend, Sabby Management opened a new position in TESARO, Inc. worth $7.19M.
- Sabby Management's largest Q2 2017 buy was TESARO, Inc.: 51,426 shares worth $7.19M.
- Sabby Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $95.6M increase.
- Sabby Management's biggest Q2 2017 reduction was Otonomy, Inc., cutting an estimated $3.19M.
- Sabby Management fully exited Amgen in Q2 2017, selling an estimated $6.09M.
- Sabby Management's ten largest holdings make up 66% of its $1.53B portfolio in Q2 2017.
- Sabby Management opened 43 new positions and closed 84 in Q2 2017.
- Sabby Management's portfolio value fell 18% quarter-over-quarter to $1.53B.
Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.